Form 4: Bausch + Lomb Director Granted 5,255 RSUs

Bausch + Lomb Director Eduardo Alfonso received an annual grant of 5,255 restricted share units, vesting prior to the next annual shareholder meeting.

Summary

• Eduardo Alfonso, a Director of Bausch & Lomb Corp (BLCO), was granted 5,255 common shares (no par value) in the form of Restricted Share Units (RSUs).
• The transaction date for this acquisition was February 19, 2026.
• The RSUs were granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
• The acquisition price for these RSUs was $0, as it represents a grant.
• Following this transaction, Eduardo Alfonso beneficially owns 5,255 common shares.
• The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It's a routine compensation grant, indicating stable corporate governance and aligning director interests with shareholders, which is generally favorable.

Positives

• The grant of Restricted Share Units to a non-employee director aligns the director's interests with those of the shareholders, as the value of their compensation is tied to the company's stock performance.
• This is a routine compensation practice for non-employee directors, indicating stable corporate governance and compensation structures.

Future Outlook

The 5,255 Restricted Share Units granted to Director Eduardo Alfonso are scheduled to vest immediately prior to the next annual meeting of shareholders, at which point they will be settled in common shares of Bausch + Lomb Corporation.

Industry Context

StockSavvy.ai notes that the grant of Restricted Share Units to non-employee directors is a common and widely accepted practice across various industries, including healthcare and pharmaceuticals. This method of compensation is designed to align the interests of directors with long-term shareholder value creation, as the value of their compensation is directly tied to the company's stock performance. It is a standard component of corporate governance and executive compensation frameworks.

Comparison to Industry Standards

• The use of Restricted Share Units (RSUs) for non-employee director compensation is a standard practice, comparable to compensation structures at companies like Johnson & Johnson, Medtronic, and Abbott Laboratories, which often include equity components to foster long-term alignment.
• The grant of 5,255 RSUs is within the typical range for annual director equity grants at companies of similar market capitalization and industry, reflecting competitive compensation practices to attract and retain qualified board members.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The 5,255 Restricted Share Units are scheduled to vest immediately prior to the next annual meeting of shareholders.
• Upon vesting, the RSUs will be settled in common shares of Bausch + Lomb Corporation.

Key Dates

Keywords

Bausch + Lomb, BLCO, Restricted Share Units, RSU grant, insider transaction, director compensation, equity compensation, Form 4